ERBB2 and breast cancer: However, comparison of DFS among different subtypes within premenopausal patients showed, no difference in the survival between HR + and TNBC breast cancer patients and both subtypes were associated with better outcome compared to patients with HER2 amplified tumors (Fig. 1A, mean survival, TNBC vs. HER2 amplified BC 79.2 vs. 61 months, p = 0.006.